Michael Bishop to Antineoplastic Agents
This is a "connection" page, showing publications Michael Bishop has written about Antineoplastic Agents.
Connection Strength
0.481
-
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4.
Score: 0.065
-
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11.
Score: 0.061
-
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13.
Score: 0.048
-
The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma. Ann Oncol. 1993; 4 Suppl 1:1-6.
Score: 0.046
-
Overview of non-Hodgkin's lymphoma. Dis Mon. 2012 Apr; 58(4):208-18.
Score: 0.044
-
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol. 2012 Mar 10; 30(8):830-6.
Score: 0.043
-
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May; 18(5):698-707.
Score: 0.042
-
Monoclonal antibody therapy. Front Biosci. 2006 May 01; 11:1620-35.
Score: 0.029
-
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant. 2005 Aug; 11(8):593-9.
Score: 0.028
-
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Clin Breast Cancer. 2003 Apr; 4(1):39-45.
Score: 0.023
-
Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. Int J Oncol. 1998 Oct; 13(4):791-9.
Score: 0.017
-
Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Bone Marrow Transplant. 1996 Jun; 17(6):951-6.
Score: 0.015
-
Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S94-100.
Score: 0.010
-
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. Biol Blood Marrow Transplant. 2009 Aug; 15(8):963-70.
Score: 0.009